Prognostic value of a five-lncRNA signature in esophageal squamous cell carcinoma

Lan Zhang, Pan Li, Enjie Liu, Chenju Xing, Di Zhu, Jianying Zhang, Weiwei Wang, Guozhong JiangCancer 2020 · DOI

Introduction

Esophageal squamous cell carcinoma (ESCC) is a highly aggressive malignancy and a leading cause of cancer-related mortality, particularly in China. Due to the subtle nature of early symptoms, many patients are diagnosed at advanced stages, resulting in poor five-year survival rates. Currently, clinical prognosis and treatment strategies rely heavily on the Tumor-Node-Metastasis (TNM) staging system. However, as an anatomical assessment, TNM staging often fails to account for the significant molecular heterogeneity of tumors. Patients with identical TNM stages can experience vastly different clinical outcomes, highlighting an urgent need for robust molecular biomarkers to enable individualized prognosis and tailored therapeutic interventions.

Methodology and Signature Construction

To address this gap, researchers developed a multi-lncRNA signature using a combination of bioinformatics and experimental validation across three distinct cohorts:

  1. Screening and Construction: Utilizing public data from the Gene Expression Omnibus (GSE53624, n=119) as a training set, the team identified long non-coding RNAs (lncRNAs) significantly associated with overall survival. Through Cox regression analysis, they narrowed the candidates to a five-lncRNA signature: AC007179.1, MORF4L2-AS1, RP11-488I20.9, RP13-30A9.2, and RP4-735C1.6.
  2. Risk Scoring Model: A mathematical formula was established where a patient’s risk score is calculated by the weighted expression levels of these five lncRNAs. Within this panel, MORF4L2-AS1, AC007179.1, and RP4-735C1.6 were identified as risk factors, while RP13-30A9.2 and RP11-488I20.9 were found to be protective.
  3. Multi-Platform Validation: The signature was validated using two independent experimental cohorts from Anyang Tumor Hospital: a test set of 98 paired tissues analyzed via Next-Generation Sequencing (RNA-seq) and a validation set of 84 tissues analyzed via qRT-PCR.

Results: Survival Stratification and Predictive Accuracy

The five-lncRNA signature demonstrated high efficacy in stratifying patients into high- and low-risk groups across all cohorts. In the training set, low-risk patients achieved a median survival of 4.01 years, compared to just 1.75 years for high-risk patients. The 3-year survival rate for the high-risk group was 23.73%, significantly lower than the 66.67% observed in the low-risk group.

Survival analysis, risk score distributions, and lncRNA expression heatmaps for the training (A-C), test (D-F), and validation (G-I) cohorts.

Multivariable Cox regression analyses confirmed that the risk score is an independent predictor of survival, maintaining its significance even when adjusted for age, sex, and TNM stage. Furthermore, time-dependent ROC curve analysis showed that the five-lncRNA signature (AUC = 0.690 at 5 years) outperformed the traditional TNM stage (AUC = 0.643). The highest predictive accuracy was achieved by combining the signature with TNM staging, resulting in an AUC of 0.742.

Biological Insights and Functional Prediction

To understand the biological rationale behind the signature, the researchers performed Pearson correlation and KEGG pathway analysis. The results suggested that these five lncRNAs are closely associated with critical oncogenic pathways, including p53, ErbB, and MAPK signaling. This molecular link suggests that the signature reflects the underlying biological drivers of tumor progression rather than just anatomical extent.

Conclusion and Future Directions

The five-lncRNA signature represents a promising prognostic tool for ESCC, offering superior predictive power compared to standard TNM staging. While these findings are robust across three cohorts and multiple detection platforms, further research is required to elucidate the specific molecular mechanisms by which these lncRNAs influence cancer progression. Future large-scale, multi-center prospective trials will be essential to standardize the signature for routine clinical diagnostic use.

Summary updated

Abstract

The five-lncRNA signature could be a good prognostic biomarker for ESCC patients and has important clinical value.
BibTeX
@inproceedings{zhang2020prognostic,
  author = {Lan Zhang and Pan Li and Enjie Liu and Chenju Xing and Di Zhu and Jianying Zhang and Weiwei Wang and Guozhong Jiang},
  title = {{Prognostic value of a five-lncRNA signature in esophageal squamous cell carcinoma}},
  booktitle = {Cancer},
  year = {2020},
  doi = {10.1186/s12935-020-01480-9},
}
Figure